Document Detail

New regimens for reducing the duration of the treatment of drug-susceptible pulmonary tuberculosis.
MedLine Citation:
PMID:  22267888     Owner:  NLM     Status:  Publisher    
Tuberculosis (TB) remains an important health problem worlwide. The structure necessary for delivering TB treatment and implementing the directly observed treatment accounts for more than two-thirds of its final cost. Furthemore, although with efficacy greater than 90%, the effectiveness of present treatment regimens ranges from 55-85%, depending on the setting, mainly due to poor adherence. Duration of treatment with the current first-line anti-TB drugs is a minimum of 6 months. Reducing the duration of the treatment from six to two months or less could result in significant increase of adherence to treatment and cost reduction. The aim of this review is to highlight potential new agents or new drug combinations that could reduce the time of treatment of drug-susceptible TB, currently under study or recently evaluated through clinical trials. We conducted a literature search in the English language for clinical studies as well as an electronic computer-assisted and manual search. The literature search was conducted on November 2010, using MEDLINE (2000-2010), EMBASE (2000-2010) and the National Institute of Health (NIH) Clinical Trials Register database (2000-2010). Most of the new agents identified as anti-TB drug candidates are still in the preclinical phases. Nitroimidazole-PA-824 and fluoroquinolones are evaluated while two first line drugs - rifampicin and rifapentine -are re-evaluated to optimize their efficacy in new ultra-short anti-TB regimens through phases II/III clinical studies. A summary of the studies are presented, with their potential to change recommendations for TB treatment in the near future.
Marcus B Conde; José R Lapa E Silva
Related Documents :
3045798 - Basic and clinical aspects of the activity of the new monoamine oxidase inhibitors.
2908748 - The gastric proton pump, a target for neuroleptics and antidepressant drugs?
12369608 - Pharmacology and pharmacokinetics of milnacipran.
7633328 - Chronic parenteral antidepressant treatment in rats: unaltered levels and processing of...
9025778 - Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotox...
22897878 - Transcriptional data: a new gateway to drug repositioning?
Publication Detail:
Journal Detail:
Title:  Drug development research     Volume:  72     ISSN:  0272-4391     ISO Abbreviation:  -     Publication Date:  2011 Sep 
Date Detail:
Created Date:  2012-1-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8204468     Medline TA:  Drug Dev Res     Country:  -    
Other Details:
Languages:  ENG     Pagination:  501-508     Citation Subset:  -    
Instituto de Doenças do Tórax, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Grant Support
U2R TW006883-08//FIC NIH HHS

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Clinical aspects of Chagas disease and implications for novel therapies.
Next Document:  Predictors of Medication Adherence in Patients with Rheumatoid Arthritis.